HomepageSH0 • FRA
Shionogi
€ 13,10
15 jan, 17:33:57 GMT+1 · EUR · FRA · Disclaimer
AandeelGLeaf-logoKlimaatkanjerEffect wordt verhandeld in DEHoofdkantoor in JP
Vorige slotkoers
€ 13,40
Dag-range
€ 13,10 - € 13,10
Jaar-range
€ 11,67 - € 16,20
Beurswaarde
1,97 bln. JPY
Gem. volume
13,00
Koers/winst
-
Dividendrendement
-
Primaire beurs
TYO
CDP-klimaatveranderingsscore
A
Marktnieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(JPY)sep 2024Wijziging j-o-j
Opbrengst
116,38 mld.-4,00%
Bedrijfskosten
52,93 mld.-3,66%
Netto inkomsten
52,50 mld.9,30%
Netto winstmarge
45,1113,86%
Winst per aandeel
EBITDA
53,13 mld.-5,14%
Effectief belastingtarief
8,28%
Totale activa
Totale passiva
(JPY)sep 2024Wijziging j-o-j
Contanten en kortetermijnbeleggingen
303,40 mld.20,22%
Totale activa
1,46 bln.3,34%
Totale passiva
145,93 mld.-18,09%
Totaal aandelenvermogen
1,31 bln.
Uitstaande aandelen
850,69 mln.
Koers-boekwaardeverhouding
0,01
Rendement op activa
8,22%
Rendement op kapitaal
9,10%
Nettomutatie in liquide middelen
(JPY)sep 2024Wijziging j-o-j
Netto inkomsten
52,50 mld.9,30%
Operationele kasstroom
45,30 mld.220,14%
Kasstroom uit beleggingen
-17,63 mld.47,30%
Kasstroom uit financiering
-1,11 mld.94,50%
Nettomutatie in liquide middelen
21,45 mld.158,43%
Vrije kasstroom
8,02 mld.135,46%
Over
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana. Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines. In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan. Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV. The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index. In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Opgericht
17 mrt 1878
Hoofdvestiging
Werknemers
4.959
Zoeken
Zoekopdracht wissen
Zoekfunctie sluiten
Google-apps
Hoofdmenu